Spectral AI Raises Up to $5 Million Financing Strengthening Financial Position for FDA Pathway
Spectral AI has secured up to $5 million in equity financing through an at-the-market transaction, to be completed in two tranches. The funds will partially be used to retire outstanding obligations with Yorkville Advisors. This financing supports the company's progress toward FDA submission for its DeepView AI®-Burn system, targeted for first half of 2025. The transaction, involving equity and pre-funded warrants with institutional investors, strengthens the company's balance sheet and operational flexibility. The company continues to receive non-dilutive U.S. Government funding to advance its AI-driven diagnostic solutions in wound care.
Spectral AI ha ottenuto fino a 5 milioni di dollari in finanziamenti azionari attraverso una transazione sul mercato, che sarà completata in due tranche. I fondi saranno parzialmente utilizzati per estinguere obbligazioni pendenti con Yorkville Advisors. Questo finanziamento supporta i progressi dell'azienda verso la presentazione all'FDA per il suo sistema DeepView AI®-Burn, previsto per la prima metà del 2025. La transazione, che coinvolge azioni e warrant pre-finanziati con investitori istituzionali, rafforza il bilancio dell'azienda e la flessibilità operativa. L'azienda continua a ricevere finanziamenti non diluitivi dal governo degli Stati Uniti per promuovere le sue soluzioni diagnostiche basate sull'IA nella cura delle ferite.
Spectral AI ha asegurado hasta 5 millones de dólares en financiación de capital a través de una transacción en el mercado, que se completará en dos tramos. Los fondos se utilizarán parcialmente para saldar obligaciones pendientes con Yorkville Advisors. Este financiamiento apoya el progreso de la empresa hacia la presentación a la FDA de su sistema DeepView AI®-Burn, programado para la primera mitad de 2025. La transacción, que involucra acciones y warrants prefinanciados con inversores institucionales, fortalece el balance de la empresa y su flexibilidad operativa. La empresa sigue recibiendo financiación no dilutiva del gobierno de los EE. UU. para avanzar en sus soluciones diagnósticas impulsadas por IA en el cuidado de heridas.
스펙트럴 AI는 시장 거래를 통해 최대 500만 달러의 자본 조달을 확보했으며, 이는 두 개의 분할로 완료될 예정입니다. 이 자금은 부분적으로 요크빌 어드바이저스에 대한 미지급 채무를 상환하는 데 사용될 것입니다. 이 자금 조달은 2025년 상반기에 예정된 DeepView AI®-Burn 시스템에 대한 FDA 제출을 향한 회사의 진행 상황을 지원합니다. 기관 투자자와의 거래로, 자본과 사전 자금 지원 워런트를 포함하여 회사의 재무 상태와 운영 유연성을 강화합니다. 회사는 상처 치료 분야에서 AI 기반 진단 솔루션을 발전시키기 위해 미국 정부의 비희석 자금을 계속해서 받고 있습니다.
Spectral AI a sécurisé jusqu'à 5 millions de dollars en financement par actions via une transaction sur le marché, qui sera complétée en deux tranches. Les fonds seront en partie utilisés pour régler les obligations en cours auprès de Yorkville Advisors. Ce financement soutient les progrès de l'entreprise vers la soumission à la FDA de son système DeepView AI®-Burn, prévu pour le premier semestre 2025. La transaction, impliquant des actions et des bons de souscription préfinancés avec des investisseurs institutionnels, renforce le bilan de l'entreprise et sa flexibilité opérationnelle. L'entreprise continue de recevoir des financements non dilutifs du gouvernement américain pour faire avancer ses solutions de diagnostic basées sur l'IA dans les soins des plaies.
Spectral AI hat bis zu 5 Millionen Dollar an Eigenkapitalfinanzierung durch eine Markttransaktion gesichert, die in zwei Tranchen abgeschlossen wird. Die Mittel werden teilweise verwendet, um ausstehende Verpflichtungen gegenüber Yorkville Advisors zu begleichen. Diese Finanzierung unterstützt den Fortschritt des Unternehmens in Richtung FDA-Einreichung für sein DeepView AI®-Burn-System, das für die erste Hälfte von 2025 angestrebt wird. Die Transaktion, die Eigenkapital und vorfinanzierte Warrants mit institutionellen Investoren umfasst, stärkt die Bilanz des Unternehmens und die operative Flexibilität. Das Unternehmen erhält weiterhin nicht verwässernde Gelder der US-Regierung, um seine KI-gesteuerten Diagnoselösungen in der Wundversorgung voranzutreiben.
- Secured $5 million in equity financing
- On track for FDA submission of DeepView AI-Burn system in H1 2025
- Receiving additional non-dilutive government funding
- Dilutive equity financing through at-the-market offering
- Outstanding debt obligations requiring retirement
Insights
This
The company's dual funding approach - combining private investment with non-dilutive government funding - creates a more stable financial foundation for their FDA approval pursuit. However, investors should note the dilutive impact of the equity offering. The targeted H1 2025 FDA submission timeline for DeepView AI-Burn provides a clear regulatory catalyst, though success isn't guaranteed. For a small-cap company in the highly competitive AI healthcare space, maintaining adequate funding through the regulatory process is crucial.
The DeepView AI-Burn system represents a potentially significant advancement in wound care diagnostics. The technology's focus on enabling faster, more accurate treatment decisions addresses a critical need in burn assessment, where timing and precision are essential for patient outcomes. The FDA submission timeline in H1 2025 suggests confidence in their clinical data and regulatory preparation.
The continued government funding support indicates recognition of the technology's potential value in healthcare settings. The AI-driven diagnostic approach could standardize burn assessment, reducing subjective variation in diagnosis. However, the path to FDA approval remains complex, particularly for AI-based medical devices, requiring robust validation of both clinical efficacy and algorithm reliability.
DALLAS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the successful completion of an approximate
The equity financing was made possible through a strategic financing arrangement with institutional investors, a testament to Spectral AI's ability to attract significant financial support. This arrangement, which included an at-the-market offering of equity and pre-funded warrants, strengthens Spectral AI's balance sheet and enhances its operational flexibility as it pursues FDA approval.
“By completing the strategic financing arrangement and retiring the outstanding note obligations, we are reinforcing Spectral AI’s financial strength, technology development and growth trajectory,” said J. Michael DiMaio, MD, Chairman of the Board of Directors of Spectral AI. “With additional support from non-dilutive U.S. Government funding, we remain committed to advancing AI-driven diagnostic solutions that will transform wound care.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize wound care management by "Seeing the Unknown®" with its DeepView System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight toward value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to separate its Spectral IP subsidiary from the Company, and each Company’s strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Spectral AI undertakes no obligation to update any forward-looking statements except as otherwise required by law.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
When will Spectral AI (MDAI) submit its DeepView AI-Burn system to FDA?
How much funding did Spectral AI (MDAI) raise in November 2024?
What will Spectral AI (MDAI) use the new financing for?
